Cellectis
Founded 1999 Β· 1 known investors
Cellectis is a gene-editing company that uses its TALEN technology to engineer CAR T-cells from healthy donors into "off-the-shelf" allogeneic immunotherapy candidates aimed at treating cancer and potentially other diseases. It develops therapies designed to be broadly available rather than custom-made per patient.
BiotechDeep TechHealthtech
Investors Β· 1
Frequently asked questions
- What does Cellectis do?
- Cellectis is a gene-editing company that uses its TALEN technology to engineer CAR T-cells from healthy donors into "off-the-shelf" allogeneic immunotherapy candidates aimed at treating cancer and potentially other diseases. It develops therapies designed to be broadly available rather than custom-made per patient.
- Who are Cellectis's investors?
- Cellectis's investors include Ridgeback Capital.